Diagnostic Accuracy of Visceral Adiposity Index in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Xianhao Yi
Third Xiangya Hospital, Central South University

Shaihong Zhu (shzhu@csu.edu.cn)
Third Xiangya Hospital, Central South University

Liyong Zhu
Third Xiangya Hospital, Central South University

Research Article

Keywords: Diagnostic accuracy, Visceral adiposity index, Nonalcoholic fatty liver disease, Meta-analysis

Posted Date: December 13th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1137007/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Many studies have shown that visceral adiposity index (VAI) is valuable in the diagnosis of nonalcoholic fatty liver disease (NAFLD), but the accuracy of VAI in the diagnosis of NAFLD is not consistent. We aimed to assess the VAI as a predictor of NAFLD.

**Methods:** The Cochrane Library, PubMed, Embase, and other databases were searched to collect all the documents that meet the inclusion criteria. The retrieval period is from the establishment of the database to September 2021. The methodological quality of the included studies was evaluated using the quadas-2 tool. The heterogeneity among the studies was analyzed by the Cochran-Q test and $I^2$ test, and the appropriate model was selected according to the heterogeneity. The diagnostic efficacy of VAI was evaluated by meta-analysis and a Fagan diagram was drawn to evaluate the diagnostic ability of VAI.

**Results:** A total of 9 studies were included. The overall quality of the included studies was good. Meta-analysis showed that the combined sensitivity (Sen combined) of VAI in the diagnosis of NAFLD was 0.70 [95% CI (0.69-0.71)], the combined specificity (Spe combined) was 0.67 [95% CI (0.67-0.68)], PLR combined was 2.08 [95% CI (1.87-2.31)], NLP combined was 0.39 [95% CI (0.34-0.44)], and DOR combined was 5.81 [95% CI (4.73-7.14)]. The corresponding AUC was 0.79 [95% CI (0.75-0.82)]. Meta-regression analysis showed that the gold index was a potential source of heterogeneity ($P < 0.05$). The Fagan diagram shows that the precision of NAFLD diagnosis is 70% when the pre-test probability is set to 50% and then supplemented by VAI.

**Conclusion:** VAI has a certain value in the diagnosis of NAFLD and may be helpful in the early detection of NAFLD, but it still needed a large number of prospective studies to support this.

Background

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common disease with a prevalence of 25.24% worldwide\[^{1}\]. NAFLD is closely related to metabolic syndrome and can cause significant economic and social burdens\[^{2}\]. Early detection of NAFLD is of great importance for its treatment and prognosis, among which liver biopsy is the gold indicator for the diagnosis of NAFLD, but its invasive effect limits its clinical application. Noninvasive diagnostic methods include MRI, CT, NFS, FIB-4, etc., but they have disadvantages such as high cost and complicated indicators\[^{3}\]. Clinical and epidemiological studies have shown that visceral fat is closely related to NAFLD\[^{4}\]. Visceral adiposity index (VAI) is a new scoring system based on waist circumference (WC), body mass index (BMI), triglyceride (TG), and high-density lipoprotein (HDL). VAI is an important index recently proposed to assess the distribution and dysfunction of visceral fat, and has been shown to be closely related to cardiovascular and cerebrovascular risk\[^{5}\]. At present, there is still controversy about whether VAI can accurately distinguish NAFLD. This study systematically evaluated whether VAI can accurately distinguish NAFLD through meta-analysis, aiming to provide a reliable evidence-based medical basis for clinical research.

Methods

**Protocol and registration**

This review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines\[^{6}\] and has been registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42021275084).

**Search strategy**

Computer retrieval of The Cochrane Library (Issue 2, 2013), PubMed, and Embase. Clinical studies related to THE diagnosis of NAFLD by VAI were searched from database establishment to September 2021. Keywords were combined with free words for retrieval. English search terms include Nonalcoholic Steatohepatitis, nonalcoholic fatty liver disease, metabolic associated fatty liver disease (MAFLD), NASH, NAFLD, MAFLD, Visceral adiposity index, VAI.

**Inclusion and exclusion criteria**

Two evaluators independently screened literature, extracted data, and evaluated the methodological quality of the included studies according to the inclusion and exclusion criteria. In case of disagreement, the dispute shall be settled through discussion or adjudicated by a third party. The inclusion criteria were as follows: (1) Published diagnostic studies of VAI in diagnosing NAFLD, And it is a primary or original study; (2) The study population consisted of hospitalized patients who received final imaging or pathological diagnosis. Sample size 30 or more. The true positive value (TP), false positive value (FP), false negative value (FN), and true negative value (TN) were provided or can be calculated statistically\[^{7}\]; (3) The test to be evaluated is VAI, and the imaging results or pathological results are the gold standards; (4) Sensitivity (Sen), specificity (Spe), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and Subject operating Characteristic curve (SROC) and area under the curve (AUC) were calculated. The exclusion criteria were: (1) Conference report; (2) Missing important data reports or unclear measurement indicators. (3) Published repeatedly in different journals, When two studies in the same institution reported the same target outcome, the quality of inclusion was better; (4) only those studies whose title was related to VAI diagnosis of NAFLD, but not related to VAI diagnosis of NAFLD.
Data extraction and quality assessment

Two independent investigators reviewed the full-text articles. The included items were evaluated as yes, no, or uncertain. Inter-researcher disagreements were resolved by consensus, or by a third investigator. Data extraction table was developed to extract data, which mainly included: the purpose of extraction was usually the general information of the study (document number, document title, year, author, statistical method), the information of patients (gender, age, etc.), and the quality evaluation of the literature. Then, the methodological quality of the included studies was evaluated according to the quadAS-2 tool developed by Whiting et al.\[8\] to evaluate the quality of diagnostic studies.

Statistical analysis

RevMan 5.3 and Meta-Disc 1.4 software were used for analysis. Spearman correlation analysis was used to investigate whether there was a threshold effect, and the SROC curve was summarized to determine whether the SROC pattern was "shoulder and arm shape". Corran-q test and I2 test were used to analyze the heterogeneity among the included studies. Appropriate models were selected according to the heterogeneity (if P > 0.05 and I2 < 50%, the fixed-effects model was used for meta-analysis; otherwise, a random-effects model was used for meta-analysis). Z-test was used to analyze the area under the SROC curve among subgroups, and the one-by-one exclusion method was used for sensitivity analysis to evaluate the stability of the study results. Stata 16.0 software was used to draw Deek's funnel plot to evaluate publication bias, and Fagan plot was used to evaluate the diagnostic ability of VAI. P < 0.05 was considered statistically significant.

Patient and public involvement

No patients or the public were involved in the research.

Ethics approval statement

This study did not involve human participants.

Results

Literature search results

529 related pieces of literature were initially detected, and 9 studies were finally included after layer by layer screening\[9-17\]. The document screening process and results are shown in Fig. 1.

Basic characteristics and quality evaluation of included studies

The included studies included 14486 cases and 23702 controls. The basic information of each study is shown in Table 1. The quadas-2 evaluation system is used for literature quality evaluation. The results show that the cumulative scores of Li et al.\[11\] and Musso et al.\[9\] are 3 points, and the cumulative scores of other studies are ≥ 4 points, indicating that the overall quality of the included literature is good (Fig. 2).

Meta-analysis results

Spearman rank correlation analysis showed that the sensitivity was positively correlated with (1-specificity) (rs = 0.450, P = 0.224), and there was no threshold effect. The heterogeneity of VAI was analyzed by Sen, Spe, PLR, NLR, and DOR. The results showed that there was heterogeneity (P < 0.001, I2 = 87.8%. P<0.001, I2=93.5%. P<0.001, I2=88.7%. P<0.001, I2=85.0%. P < 0.001, I2 = 84.0%), meta-analysis was carried out by random effect model. The results showed that the combined sensitivity (Sen combined) of VAI in the diagnosis of NAFLD was 0.70 [95% CI (0.69-0.71)], the combined specificity (Spe combined) was 0.67 [95% CI (0.67-0.68)], PLR combined was 2.08 [95% CI (1.87-2.31)], NLR combined was 0.39 [95% CI (0.34-0.44)], and DOR combined was 5.81 [95% CI (4.73-7.14)]. The corresponding AUC is 0.79 [95% CI (0.75-0.82)], as shown in Figures 3-6.

Subgroup analysis and meta-regression analysis

After subgroup analysis based on three factors: gold index, control source, and race, it is found that Sen, Spe, PLR, NLR, and DOR of VAI in the diagnosis of NAFLD with biopsy as the gold index are better than those with imaging examination as the gold standard (Table 2 for details). Meta-regression analysis shows that the gold index is a potential source of heterogeneity (Fig. 7 for details).

Sensitivity analysis and publication bias

The sensitivity analysis was carried out by excluding the included studies one by one. The results showed that the included studies had no significant impact on the results. Deek's funnel plot showed that there was no potential publication bias between included studies (P = 0.17) (Fig. 8).

Clinical application value

Draw a Fagan diagram, set the pre-test probability as 50%, and then measure VAI. When VAI ≥ 1.25, the accuracy of diagnosis of NAFLD is 70%. When VAI < 1.25, the accuracy of diagnosing NAFLD is 27% (Fig. 9), suggesting that VAI has good accuracy in diagnosing NAFLD.
Discussion

In recent years, with the improvement of living standards, the incidence rate of NAFLD has increased year by year and has been developing towards younger age. It has become one of the hidden threats to human health. Although it is a benign disease, it will develop into cirrhosis and even hepatocellular carcinoma with the development of the disease, and reduce the survival rate of the patients. Therefore, early diagnosis of NAFLD is very important for its treatment and prognosis. The study found that VAI is closely related to the incidence of NAFLD and can be used as one of the indicators for screening NAFLD in the general population, but there is no conclusion about its diagnostic efficacy.

Meta-analysis showed that Sen, Spe, NLP, DOR, and AUC of VAI in the diagnosis of NAFLD were 0.70, 0.67, 2.08, 0.39, and 0.79 respectively. It is generally believed that the diagnostic efficacy of AUC is low at 0.50-0.60, medium at 0.70-0.90, higher at > 0.90, PLR greater than 10.00, and NLR less than 1.00, indicating that it can be diagnosed or excluded. From the above analysis, it is found that VAI has medium diagnostic efficiency in diagnosing NAFLD, but it can not accurately diagnose NAFLD.

Heterogeneity is an inevitable problem in meta-analysis. There is heterogeneity caused by the non-threshold effect in this analysis. Through subgroup analysis and meta-regression analysis, it is found that heterogeneity is mainly caused by differences in gold indicators. Sen, Spe, PLR, NLR, and DOR with disease examination as gold indicators are higher than those in the imaging examination subgroup, indicating that the diagnostic efficiency of disease examination is better than that of imaging examination. However, imaging examination is still the main means of clinical diagnosis of NAFLD because of its advantages of non-invasive and high accuracy. According to the source of control, the diagnostic odds ratio of a healthy population is higher than that of a non-NAFLD population, indicating that VAI can more accurately diagnose NAFLD when compared with the healthy population. According to race, the diagnostic odds ratio of the European populations is higher than that of the Asian population, indicating that VAI can more accurately diagnose NAFLD in the European populations. VAI is a model based on the clinical data of 315 Italian healthy subjects collected by Marco et al. and established by regression analysis. There are significant differences in body fat distribution between European populations and Asian populations. This evidence can explain the differences in the diagnostic efficacy of VAI in different control sources and different races.

In addition, the Fagan diagram shows that when the prior probability is 50%, the posterior probabilities of VAI ≥ 1.25 and VAI < 1.25 are 70% and 27% respectively. That is, it is assumed that the probability of a diagnosis of NAFLD is 50% according to symptoms and personal tests of doctors. After VAI measurement, if VAI ≥ 1.25, the accuracy of diagnosis of NAFLD will be increased to 70%. On the contrary, if VAI < 1.25, the accuracy of diagnosis of NAFLD will be 20%. Therefore, VAI diagnosis of NAFLD has a good clinical application prospect.

Strengths and limitations

This study has the following advantages: (1) all the included studies adopt strict inclusion criteria, and the overall score is high. (2) Subgroup analysis and meta-regression analysis were used to further evaluate that the analysis results were stable and reliable. (3) Fagan diagram shows that VAI has good clinical value.

However, there are still some deficiencies in this study, which is superior to the limitations of Meta-Analysis: (1) failure to obtain non-braided literature may cause publication bias. (2) Only English documents are included in the included documents, but other Chinese, Japanese, German and other documents are not included, which affects the comprehensiveness of the data. (3) Because the critical value of VAI for NAFLD diagnosis is not unified and affected by different NAFLD diagnostic criteria, it may have a certain impact on the final result.

Conclusion

In conclusion, VAI has a certain value in the diagnosis of NAFLD and is feasible in clinical application. However, further large samples, multi-center data, and unified NAFLD diagnostic criteria are still needed to verify. With the deepening of follow-up research, VAI will have a wide application prospect.

Abbreviations

VAI: visceral adiposity index; NAFLD: nonalcoholic fatty liver disease; WC: waist circumference; BMI: body mass index; TG: triglyceride; HDL: high-density lipoprotein; MAFLD: metabolic associated fatty liver disease; TP: true positive value; FP: false positive value; FN: false negative value; TN: true negative value; Sen: Sensitivity; Spe: specificity; +LR: positive likelihood ratio; -LR: negative likelihood ratio; DOR: diagnostic odds ratio; SROC: Subject operating Characteristic curve; AUC: area under the curve.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication
Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflict of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions

Xianhao Yi: literature search, data extraction, data analysis, manuscript preparation.

Liyong Zhu: study concepts and design, data extraction, critical revision.

Shaihong Zhu: study concepts and design, data extraction, critical revision.

All authors have participated sufficiently in the study and approved the final version.

Acknowledgements

Not applicable.

References

1. Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.

2. Younossi Z, Anstee Q M, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & Hepatology 2018; 15: 11-20.

3. Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019; 156: 1264-81.e4.

4. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48.

5. Amato M C, Giordano C, Galia M, et al. Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-2.

6. McInnes M D F, Moher D, Thombs B D, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. Jama 2018; 319: 388-96.

7. Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochemia medica 2016; 26: 297-307.

8. Whiting P F, Rutjes A W, Westwood M E, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.

9. Musso G, Cassader M, Gambino R. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. Hepatology 2012; 56: 788-9.

10. Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1209-22.

11. Li L, You W, Ren W. The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. Acta Diabetol 2017; 54: 905-11.

12. Vassilatou E, Lafoyianni S, Vassiliadi D A, et al. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. Maturitas 2018; 116: 1-7.

13. Fu C P, Ali H, Rachakonda V P, et al. The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American women. PLoS One 2019; 14: e0224942.

14. Villanueva-Ortega E, Garecs-Hernandez M J, Herrera-Rosas A, et al. Gender-specific differences in clinical and metabolic variables associated with NAFLD in a Mexican pediatric population. Ann Hepatol 2019; 18: 693-700.

15. Cen C, Wang W, Yu S, et al. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. Hepatology international 2020; 14: 808-16.
16. Lin I T, Lee M Y, Wang C W, et al. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. *Int J Environ Res Public Health* 2021; 18.

17. Vural Keskinler M, Mutlu H H, Sirin A, et al. Visceral Adiposity Index As a Practical Tool in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. *Metab Syndr Relat Disord* 2021; 19: 26-31.

18. Younossi Z M. Non-alcoholic fatty liver disease - A global public health perspective. *J Hepatol* 2019; 70: 531-44.

19. Rinella M E, Sanyal A J. Management of NAFLD: a stage-based approach. *Nature reviews Gastroenterology & hepatology* 2016; 13: 196-205.

20. Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. *Bmj* 2021; 372: n365.

### Tables

#### Table 1 Basic characteristics of included studies

| Author | Year | country | Gold index | Control source | Race | Cases number | Control number | Cut-off | TP   | FP   | FN   | TN   |
|--------|------|---------|------------|----------------|------|--------------|----------------|---------|------|------|------|------|
| Cen¹   | 2020 | China   | Ultrasonographic | Non-NAFLD | Asian | 6261         | 10207         | 1.59    | 4414 | 3205 | 1847 | 7002 |
| Fedchuk² | 2014 | France  | Biopsy     | Non-NAFLD | European | 241        | 83           | 1.25    | 190  | 7    | 51   | 76   |
| Fu³    | 2019 | America | Computed tomography | Non-NAFLD | European | 40         | 67           | 1.46    | 35   | 42   | 5    | 25   |
| Keskinler⁴ | 2020 | Turkey  | Biopsy     | Healthy | European | 57         | 57           | 1.78    | 45   | 16   | 12   | 41   |
| Li⁵    | 2017 | China   | Ultrasonographic | Non-NAFLD | Asian | 7324        | 12480       | 1.89    | 4988 | 4152 | 2336 | 8328 |
| Lin⁶   | 2021 | China   | Ultrasonographic | Non-NAFLD | Asian | 354         | 410          | -       | 293  | 192  | 61   | 218  |
| Musso⁷ | 2012 | Italy   | Ultrasonographic | Healthy | European | 41         | 82           | 1.9     | 31   | 23   | 10   | 59   |
| Ortega⁸ | 2019 | Mexico  | Ultrasonographic | Non-NAFLD | European | 36         | 158          | 2.33    | 28   | 75   | 8    | 83   |
| Vassilatou⁹ | 2018 | Greece  | Ultrasonographic | non-NAFLD | European | 132        | 158          | -       | 85   | 34   | 47   | 124  |

Abbreviations: TP, True positive value; FP, False positive value; FN, False negative value; TN, True negative value; NAFLD, Nonalcoholic fatty liver disease.

#### Table 2 Subgroup and Meta-regression analysis of VAI in the diagnosis of NAFLD in included studies

| Subgroup | Number of studies | Sen|95%CI | Spe|95%CI | PLR|95%CI | NLR|95%CI | DOR|95%CI | RDOR|95%CI | P  |
|----------|-------------------|----|------|----|------|----|------|----|------|----|------|-----|------|----|
| gold index |                   |    |      |    |      |    |      |    |      |    |      |     |      |    |
| biopsy    | ²,²               | 0.79|0.74-0.83| 0.84|0.76-0.89| 5.00|1.27-19.72| 0.24|0.19-0.30| 19.79|4.8-81.63| 4.06|1.87-8.79| 0.0036 |
| imaging examination | ³-⁹ | 0.70|0.69-0.70| 0.67|0.67-0.68| 1.99|1.80-2.19| 0.43|0.39-0.47| 4.96|4.26-5.79|     |      |    |
| control source |                   |    |      |    |      |    |      |    |      |    |      |     |      |    |
| Healthy   | ²,³               | 0.78|0.68-0.85| 0.72|0.64-0.79| 2.75|2.06-3.67| 0.31|0.21-0.46| 8.78|4.76-16.06| 1.38|0.35-5.40| 0.5898 |
| Non-NAFLD | ¹,¹⁴,⁹             | 0.70|0.69-0.70| 0.67|0.67-0.68| 2.01|1.80-2.25| 0.39|0.35-0.45| 5.55|4.48-6.88|     |      |    |
| Race      |                   |    |      |    |      |    |      |    |      |    |      |     |      |    |
| Asian     | ³,⁴,⁹,⁸           | 0.70|0.69-0.70| 0.67|0.67-0.68| 2.04|1.86-2.24| 0.43|0.39-0.48| 4.84|4.07-5.75| 1.70|0.69-4.22| 0.2091 |
| European  | ¹,³,₅,₇         | 0.76|0.72-0.79| 0.67|0.64-0.71| 2.66|1.61-4.38| 0.33|0.24-0.45| 8.39|4.38-16.05|     |      |    |

Abbreviations: Sen, Sensitivity; Spe, Specificity; PLR, Positive likelihood ratio; NLR, Negative likelihood ratio; DOR, Diagnostic odds ratio; RDOR, Relative diagnostic odds ratio; NAFLD, Nonalcoholic fatty liver disease.
Figures

Figure 1

Flow chart of literature screening
Figure 2
Methodological quality of the included studies assessed by the QUADAS-2 tool

Figure 3
Forest plot assessing the pooled sensitivity and specificity of VAI in the diagnosis of NAFLD in included studies

Figure 4
Forest plot assessing the pooled positive and negative likelihood ratios of VAI in the diagnosis of NAFLD in included studies
Figure 5
Forest plot assessing the diagnostic odds ratio of VAI in the diagnosis of NAFLD in included studies

Figure 6
Summary receiver operating curve of the diagnosis performance of VAI for NAFLD in included studies

Figure 7
Meta-regression analysis of VAI in the diagnosis of NAFLD in included studies

Figure 8
Deek's funnel plot assessing the publication bias of included studies

Figure 9
Fagan's nomogram showing the diagnostic value of VAI for NAFLD